Proposal to decline inactive applications


29 April 2019 - To help make its decision-making process clearer, PHARMAC is seeking feedback on a proposal to make decisions to decline funding applications.

These decisions are:.

  • Cisapride for gastro-intestinal motility disorders
  • Melatonin widened access for primary insomnia in patients aged 55 years and older and secondary insomnia associated with dementia
  • Methylphenidate widened access for depression and traumatic brain injury
  • Paracetamol sustained release for pain
  • Sibutramine hydrochloride for severe obesity
  • Simeprevir for chronic hepatitis C genotype 1
  • Temozolomide widened access for glioma (brain tumour)
  • Trastuzumab for HER2-positive advanced gastric cancer

These applications are inactive, meaning that PHARMAC is not currently actively undertaking any work to progress the application for funding.

Read PHARMAC consultation

Michael Wonder

Posted by:

Michael Wonder